The regulatory agency has approved local medicine ‘Cryptolepis Sanguinolenta’, popularly known as Nibima, for clinical trial on COVID-19 treatment.
The Food and Drugs Authority (FDA) has approved Ghana’s first herbal medicine for clinical trial on COVID-19 treatment.
This follows results from laboratory studies conducted by the Kwame Nkrumah University of Science and Technology (KNUST) research team.
This means the medicine, Cryptolepis Sanguinolenta, locally known as Nibima stands a better chance of being used to treat COVID-19 if it is approved after the trial.
A statement signed and released by FDA CEO Delese Darko said the authority remains committed to protect the health and safety of consumers.
Below is the full statement:
PRESS RELEASE-FDA APPROVES FIRST HERBAL MEDICINE FOR CLINICAL TRIAL FOR COVID-19 TREATMENT
Case update
At least 416 COVID-19 deaths have been confirmed by the Ghana Health Service. The country has also recorded a total of 67,010 confirmed cases and 61,236 recoveries. Active cases stand at 5,358.
